Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role
April 30, 2013 14:44 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 30 April 2013 - Addex...
Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence
April 30, 2013 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Data reinforces broad therapeutic potential of...
Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441
April 24, 2013 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} ADX71441, a novel oral small molecule GABA-B...
Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant
April 22, 2013 01:47 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Dipraglurant, an mGlu5 negative allosteric modulator,...
Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)
April 18, 2013 01:02 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Dipraglurant, an mGlu5 negative allosteric...
Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)
March 21, 2013 12:30 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} $1 MM grant by The Michael J. Fox Foundation to be...
Addex Shareholders Approve All Board Proposals at Annual General Meeting
March 20, 2013 02:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 20 March 2013 - Addex...
Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research
March 19, 2013 02:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Grant to be used to help fund further human clinical...
Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor
March 04, 2013 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Partnership to demonstrate the potential to...
Addex Therapeutics Reports 2012 Financial Results
February 28, 2013 01:31 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} 2012 Financial Highlights CHF20.8 million of...